Anchiano Therapeutics
- Company typePrivate
- Founded2004
- HeadquartersJerusalem, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Anchiano Therapeutics firmographics
Firmographics- Name
- Anchiano Therapeutics
- Website
- https://anchiano.com
- Company type
- Private
- Founded year
- 2004
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Anchiano Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)
Keywords
Where Anchiano Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Anchiano Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Anchiano Therapeutics product offering
Product offeringCore offering
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer. The company engages in oncology drug discovery and advances therapeutic candidates through preclinical and clinical development stages.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel Cancer Therapies (Pipeline)
Companies that use Anchiano Therapeutics
Customer profileIdeal customer profiles1 record
Anchiano Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Anchiano Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Anchiano Therapeutics competitors and assessment
Company assessmentDirect peers
- BioLineRx: Israel-based clinical-stage biopharmaceutical company developing oncology assets with a similar small-cap Israeli biotech footprint. Closest direct peer on geography, stage, and therapeutic focus.
- Compugen: Israel-headquartered clinical-stage biotechnology company focused on immuno-oncology drug discovery. Comparable in geography, clinical-stage profile, and oncology pipeline.
- OncoSec Medical: Clinical-stage oncology company with intratumoral plasmid DNA gene therapy approaches analogous to Anchiano's BC-819 class of constructs, sharing modality and development stage.
- RedHill Biopharma: Israel-based specialty biopharmaceutical company with clinical-stage assets spanning oncology and other indications. Comparable Israeli clinical-stage footprint.
- Kitov Pharma: Israeli clinical-stage pharmaceutical company with oncology and pain assets. Similar Israeli small-cap clinical-stage operating profile.
- Cellect Biotechnology: Israel-based clinical-stage biotechnology company developing selective cell-based oncology therapies. Comparable Israeli clinical-stage oncology peer.
- Moleculin Biotech: U.S.-based small clinical-stage oncology pharmaceutical company developing novel therapies for hard-to-treat tumors. Similar small-cap clinical-stage profile.
- Kazia Therapeutics: Clinical-stage oncology company developing small-molecule therapies for brain and other cancers. Comparable small clinical-stage oncology footprint.
- SELLAS Life Sciences: Late-clinical-stage biopharmaceutical company developing novel cancer immunotherapies. Similar small clinical-stage oncology biotech profile and capital-raising cadence.
Broad incumbents
- Teva Pharmaceutical Industries: Israel-headquartered global pharmaceutical incumbent with oncology and specialty franchises. Included as the dominant Israeli pharma incumbent for ecosystem perspective, not as direct competition.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Anchiano Therapeutics social profiles
Digital presenceAnchiano Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anchiano Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Anchiano Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anchiano Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anchiano Therapeutics
What does Anchiano Therapeutics do?
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer. The company engages in oncology drug discovery and advances therapeutic candidates through preclinical and clinical development stages.
When was Anchiano Therapeutics founded?
Anchiano Therapeutics was founded in 2004. It employs 11 to 50 people.
Where is Anchiano Therapeutics based?
Anchiano Therapeutics is headquartered in Jerusalem, Israel, in the Middle East region.
Who are Anchiano Therapeutics's main competitors?
Direct peers on record are BioLineRx, Compugen, OncoSec Medical, RedHill Biopharma, Kitov Pharma, Cellect Biotechnology, Moleculin Biotech, Kazia Therapeutics and SELLAS Life Sciences. Teva Pharmaceutical Industries is listed as a broad incumbent.
Does Anchiano Therapeutics have an API?
No public API is recorded for Anchiano Therapeutics.
What industry is Anchiano Therapeutics in?
Anchiano Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown). Its NAICS code is 5417 and its SIC code is 2833.